Novartis AG
REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
Last updated:
Abstract:
The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
Status:
Application
Type:
Utility
Filling date:
6 Oct 2021
Issue date:
17 Mar 2022